Ascendis Pharma director Lars Holtug sold a small portion of his holdings in the biotechnology company this week, according to a new regulatory filing, as ASND shares trade near the upper end of their 52-week range following strong commercial growth and the resolution of a major patent dispute.
Holtug sold 236 Ascendis ordinary shares on September 2 at $264.1296 per share, giving the transaction a total value of approximately $62,335. The sale left him directly owning 4,000 shares, according to the Form 4 filed with the Securities and Exchange Commission Thursday afternoon.
Based on his reported holdings, Holtug disposed of roughly 5.6% of the 4,236 shares he directly owned before the transaction and retained about 94.4% of that position.
The filing does not state why Holtug sold the shares. It also does not indicate that the transaction was made under a Rule 10b5-1 trading plan, a type of predetermined trading arrangement commonly used by corporate insiders. That absence does not establish any particular motive for the sale, and the relatively small size of the transaction gives investors little basis to interpret it on its own as a change in management’s view of the company.
Timing makes that distinction especially relevant.
The Form 4 was accepted by the SEC shortly after 4 p.m. Eastern time on September 3, meaning the transaction had not been publicly disclosed during Thursday’s regular trading session. Any movement in Ascendis shares before the filing became public therefore cannot reasonably be attributed to the insider sale.
ASND had closed September 2 at $267.31, up 2.7% for the session after trading as high as $268.71. Shares were around $270.87 late Thursday, roughly 1.3% higher on the day and not far below their recent 52-week high.
The stock’s recent strength has been driven by developments considerably larger than Holtug’s transaction.
Ascendis shares jumped 6.1% on August 31 after the company announced a binding global settlement with BioMarin Pharmaceutical covering YUVIWEL, its recently launched treatment for achondroplasia. The agreement removes patent disputes that had created uncertainty around one of Ascendis’ newest commercial products.
Under the proposed settlement, BioMarin will grant Ascendis a non-exclusive worldwide license allowing it to continue researching, manufacturing and commercializing YUVIWEL and other navepegritide-related products. BioMarin also agreed to dismiss related proceedings, waive certain regulatory rights and provide a covenant not to sue over covered intellectual property.
Ascendis, in return, will pay BioMarin royalties equal to 20% of U.S. net sales and 18% of net sales in the European Union, South Korea and Brazil. Those payments are scheduled to continue from the first commercial sale in each market through May 20, 2030.
The royalty burden will reduce the economics Ascendis keeps from YUVIWEL in those markets, but resolving the dispute also removes the possibility that ongoing litigation could interfere with development or commercialization. For investors evaluating ASND, the trade-off is now more measurable: Ascendis gives up a portion of future sales in exchange for substantially greater legal certainty around the franchise.
YUVIWEL is still early in its launch.
The drug generated €8 million of revenue during the second quarter, and more than 220 unique U.S. patients had enrolled through July 31 across more than 100 prescribing healthcare providers. Ascendis said more than 65% of those enrollments had received reimbursement approval.
The European Medicines Agency is reviewing YUVIWEL’s marketing application, with Ascendis expecting a decision during the fourth quarter of 2026. The company is also preparing additional development programs that could expand the addressable market for its TransCon CNP platform.
Ascendis’ broader business has been growing much faster than the YUVIWEL contribution alone would suggest.
Second-quarter product revenue reached €315 million, up 105% from a year earlier. YORVIPATH accounted for €252 million, SKYTROFA generated €55 million and YUVIWEL contributed the remaining €8 million.
Total company revenue rose to €339 million from €158 million in the prior-year quarter. Ascendis reported €220 million in operating profit and €207 million in net profit, equal to €2.83 per diluted share. On a non-IFRS basis, operating profit was €92 million and diluted earnings were €0.90 per share.
The company’s balance sheet has also strengthened. Ascendis finished June with €812 million in cash and cash equivalents, up from €616 million at the end of 2025. During the quarter, it received €158 million from selling the rare pediatric disease Priority Review Voucher awarded after YUVIWEL’s U.S. approval and completed the conversion of its outstanding $575 million of convertible senior notes.
Operating cash flow for the first six months of 2026 reached €274 million, compared with €22 million of cash used in the same period last year.
Ascendis has maintained an expectation of generating more than €500 million in operating cash flow during 2026 and has said it believes annual revenue can eventually reach €5 billion in 2030. The BioMarin agreement did not change those targets.
That financial trajectory is more consequential to the ASND investment case than Thursday’s insider disclosure.
YORVIPATH remains the company’s dominant commercial engine, and continued U.S. adoption will be important for sustaining the current pace of revenue growth. YUVIWEL, meanwhile, represents an emerging second growth opportunity whose economics are now clearer following the BioMarin settlement.
Investors will also be watching several upcoming clinical and regulatory events. Ascendis expects a European decision on YUVIWEL in the fourth quarter, plans to begin a Phase 3 study of TransCon CNP combined with TransCon hGH in pediatric achondroplasia during the same period, and is pursuing additional development in infants and patients with hypochondroplasia.
For the insider transaction itself, the next meaningful signal would be whether Holtug or other Ascendis directors and executives report additional sales, particularly if they become substantially larger or more frequent.
For now, the disclosed sale represents only 236 shares and left Holtug with 4,000 shares still directly owned. With ASND trading near recent highs, investors have more substantial factors to monitor in YORVIPATH growth, YUVIWEL adoption, the economics of the BioMarin agreement and Ascendis’ ability to deliver on its 2026 cash-flow and longer-term revenue targets.